Tilray Inc (TLRY) - Net Assets
Based on the latest financial reports, Tilray Inc (TLRY) has net assets worth $2.16 Billion USD as of November 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.93 Billion) and total liabilities ($771.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Tilray Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.16 Billion |
| % of Total Assets | 73.69% |
| Annual Growth Rate | 95.61% |
| 5-Year Change | -54.23% |
| 10-Year Change | 7513.87% |
| Growth Volatility | 1090.38 |
Tilray Inc - Net Assets Trend (2012–2025)
This chart illustrates how Tilray Inc's net assets have evolved over time, based on quarterly financial data. Also explore TLRY total assets for the complete picture of this company's asset base.
Annual Net Assets for Tilray Inc (2012–2025)
The table below shows the annual net assets of Tilray Inc from 2012 to 2025. For live valuation and market cap data, see market value of Tilray Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-05-31 | $2.04 Billion | -56.43% |
| 2024-05-31 | $4.69 Billion | +4.60% |
| 2023-05-31 | $4.49 Billion | -19.89% |
| 2022-05-31 | $5.60 Billion | +25.38% |
| 2021-05-31 | $4.47 Billion | +1075.05% |
| 2020-05-31 | $380.01 Million | +41.22% |
| 2019-05-31 | $269.10 Million | +4462.68% |
| 2018-05-31 | $-6.17 Million | -280.61% |
| 2017-05-31 | $3.42 Million | -87.28% |
| 2016-05-31 | $26.85 Million | +150.00% |
| 2015-05-31 | $10.74 Million | +3850.26% |
| 2014-05-31 | $271.84K | 0.00% |
| 2013-05-31 | $271.84K | -18.40% |
| 2012-05-31 | $333.15K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tilray Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 665121861582.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $145.45K | 0.01% |
| Other Comprehensive Income | $-59.09 Million | -2.85% |
| Other Components | $8.78 Billion | 423.54% |
| Total Equity | $2.07 Billion | 100.00% |
Tilray Inc Competitors by Market Cap
The table below lists competitors of Tilray Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Foshan Nationstar Optoelectronics Co Ltd
SHE:002449
|
$717.69 Million |
|
Brookfield Real Assets Income
NYSE:RA
|
$717.76 Million |
|
Shenzhen Etmade Automatic Equipment
SHE:300812
|
$717.83 Million |
|
Ningbo Sinyuan ZM Technology Co. Ltd. A
SHE:301398
|
$717.84 Million |
|
Dodla Dairy Limited
NSE:DODLA
|
$717.60 Million |
|
Seneca Foods Corp A
NASDAQ:SENEA
|
$717.15 Million |
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
$716.93 Million |
|
Vgi Partners Global Investments Ltd
AU:VG1
|
$716.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tilray Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,691,200,428 to 2,074,029,508, a change of -2,617,170,920 (-55.8%).
- Net loss of 3,000,620,016 reduced equity.
- Dividend payments of 1,544,000 reduced retained earnings.
- New share issuances of 161,188,000 increased equity.
- Other comprehensive income increased equity by 179,815.
- Other factors increased equity by 223,625,281.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.00 Billion | -144.68% |
| Dividends Paid | $1.54 Million | -0.07% |
| Share Issuances | $161.19 Million | +7.77% |
| Other Comprehensive Income | $179.81K | +0.01% |
| Other Changes | $223.63 Million | +10.78% |
| Total Change | $- | -55.79% |
Book Value vs Market Value Analysis
This analysis compares Tilray Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.26x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.19x to 0.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-05-31 | $1.00 | $6.16 | x |
| 2013-05-31 | $0.08 | $6.16 | x |
| 2014-05-31 | $0.81 | $6.16 | x |
| 2015-05-31 | $2.82 | $6.16 | x |
| 2016-05-31 | $5.48 | $6.16 | x |
| 2017-05-31 | $0.37 | $6.16 | x |
| 2018-05-31 | $-0.44 | $6.16 | x |
| 2019-05-31 | $13.23 | $6.16 | x |
| 2020-05-31 | $16.66 | $6.16 | x |
| 2021-05-31 | $165.43 | $6.16 | x |
| 2022-05-31 | $115.23 | $6.16 | x |
| 2023-05-31 | $72.27 | $6.16 | x |
| 2024-05-31 | $63.17 | $6.16 | x |
| 2025-05-31 | $23.30 | $6.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tilray Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -144.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -266.25%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.40x
- Recent ROE (-144.68%) is below the historical average (-19.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -28.94% | 0.00% | 0.00x | 1.03x | $-129.74K |
| 2013 | -15.45% | 0.00% | 0.00x | 1.04x | $-69.17K |
| 2014 | -15.45% | 0.00% | 0.00x | 1.04x | $-69.17K |
| 2015 | -49.03% | -1186.63% | 0.04x | 1.07x | $-6.34 Million |
| 2016 | 1.14% | 4.72% | 0.23x | 1.04x | $-2.38 Million |
| 2017 | 91.24% | 20.54% | 0.34x | 13.15x | $2.77 Million |
| 2018 | 0.00% | 79.77% | 0.42x | 0.00x | $23.45 Million |
| 2019 | -9.30% | -13.96% | 0.20x | 3.32x | $-51.95 Million |
| 2020 | -26.98% | -25.30% | 0.34x | 3.14x | $-140.54 Million |
| 2021 | -9.95% | -71.61% | 0.10x | 1.35x | $-889.65 Million |
| 2022 | -10.84% | -75.88% | 0.12x | 1.24x | $-1.16 Billion |
| 2023 | -43.81% | -231.64% | 0.14x | 1.33x | $-2.40 Billion |
| 2024 | -7.12% | -31.05% | 0.18x | 1.26x | $-802.92 Million |
| 2025 | -144.68% | -266.25% | 0.39x | 1.40x | $-3.21 Billion |
Industry Comparison
This section compares Tilray Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tilray Inc (TLRY) | $2.16 Billion | -28.94% | 0.36x | $717.68 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Tilray Inc
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and… Read more